The effect of cystic fibrosis on many organs and the frequent lung infections means that it is mostly diagnosed in childhood. Somehow, for Verônica Stasiak Bednarczuk, that diagnosis did not arrive ...

A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the ...

Doctors are enrolling patients in a groundbreaking clinical trial aimed at reducing cancer recurrence in patients with ...

University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...

Paul Nghiem, MD, PhD, and the Nghiem Lab have championed innovations in MCC treatment, delivering new treatment options, ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications.The ...

Another original article (Liu et al.) focused on the evaluation of postoperative management of patients with pheochromocytoma assessing hemodynamic stability as one of the main causes of serious ...

The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma. A decision is due on May 26, 2025.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug ...